Among its constituents, spathulenol emerged as a key bioactive compound, demonstrating strong binding affinities with multiple therapeutic targets such as AChE, BChE, α-glucosidase, and α-amylase, suggesting its potential as a dual-action agent in managing neurodegenerative and metabolic disorders. The gene discussed is ACHE; the disease is Other metabolic disease.